A. Merz

发表

Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer.

N. Serkova, A. Merz, Natalie J Serkova, 2009, Biomarkers in medicine.

P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

D. Gustafson, A. Merz, Erica L. Bradshaw, 2005, Cancer Chemotherapy and Pharmacology.

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

F. Ciardiello, S. Eckhardt, N. Serkova, 2007, Clinical Cancer Research.

Pharmacokinetics of combined doxorubicin and paclitaxel in mice.

D. Gustafson, A. Merz, M. E. Long, 2005, Cancer letters.

Thyroid hormone responsive protein Spot14 enhances catalysis of fatty acid synthase in lactating mammary epithelium[S]

N. Serkova, S. Anderson, E. Wellberg, 2014, Journal of Lipid Research.

Induction of the Unfolded Protein Response Drives Enhanced Metabolism and Chemoresistance in Glioma Cells

Laura M. Epple, Nathaniel L. Dusto, D. Bigner, 2013, PloS one.

Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer

H. Selby, S. Eckhardt, N. Serkova, 2013, PloS one.

Tissue Distribution and Metabolism of the Tyrosine Kinase Inhibitor ZD6474 (Zactima) in Tumor-Bearing Nude Mice following Oral Dosing

D. Gustafson, E. Bradshaw-Pierce, A. Merz, 2006, Journal of Pharmacology and Experimental Therapeutics.

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

D. Raben, B. Frederick, D. Gustafson, 2007, Cancer Chemotherapy and Pharmacology.

Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo

D. Ross, D. Siegel, J. Kepa, 2003, Journal of Pharmacology and Experimental Therapeutics.

142 Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts

D. Raben, D. Gustafson, A. Merz, 2004 .